» Articles » PMID: 27009094

HIV-1 Latency and Eradication: Past, Present and Future

Overview
Journal Curr HIV Res
Date 2016 Mar 25
PMID 27009094
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Background: It is well established that antiretroviral therapy (ART), while highly effective in controlling HIV replication, cannot eliminate virus from the body. Therefore, the majority of HIV-1-infected individuals remain at risk for developing AIDS due to persistence of infected reservoir cells serving as a source of virus re-emergence. Several reservoirs containing replication competent HIV-1 have been identified, most notably CD4+ T cells. Cells of the myeloid lineage, which are the first line of defense against pathogens and participate in HIV dissemination into sanctuary organs, also serve as cellular reservoirs of HIV-1. In latently infected resting CD4+ T cells, the integrated copies of proviral DNA remain in a dormant state, yet possess the ability to produce replication competent virus after cellular activation. Studies have demonstrated that modification of chromatin structure plays a role in establishing persistence, in part suggesting that latency is, controlled epigenetically.

Conclusion: Current efforts to eradicate HIV-1 from this cell population focus primarily on a "shock and kill" approach through cellular reactivation to trigger elimination of virus producing cells by cytolysis or host immune responses. However, studies revealed several limitations to this approach that require more investigation to assess its clinical application. Recent advances in gene editing technology prompted use of this approach for inactivating integrated proviral DNA in the genome of latently infected cells. This technology, which requires a detailed understanding of the viral genetics and robust delivery, may serve as a powerful strategy to eliminate the latent reservoir in the host leading to a sterile cure of AIDS.

Citing Articles

Impact of chromatin on HIV-1 latency: a multi-dimensional perspective.

Jones J, Gunderson C, Wigdahl B, Nonnemacher M Epigenetics Chromatin. 2025; 18(1):9.

PMID: 40055755 PMC: 11889793. DOI: 10.1186/s13072-025-00573-x.


Revisiting JC virus and progressive multifocal leukoencephalopathy.

Rocchi A, Sariyer I, Berger J J Neurovirol. 2023; 29(5):524-537.

PMID: 37659983 DOI: 10.1007/s13365-023-01164-w.


Controversies in the Design of Strategies for the Cure of HIV Infection.

de Gea-Grela A, Moreno S Pathogens. 2023; 12(2).

PMID: 36839593 PMC: 9961067. DOI: 10.3390/pathogens12020322.


Immunomodulatory Effects of Non-Thermal Plasma in a Model for Latent HIV-1 Infection: Implications for an HIV-1-Specific Immunotherapy.

Mohamed H, Berman R, Connors J, Haddad E, Miller V, Nonnemacher M Biomedicines. 2023; 11(1).

PMID: 36672628 PMC: 9856147. DOI: 10.3390/biomedicines11010122.


Immunometabolic Reprogramming in Response to HIV Infection Is Not Fully Normalized by Suppressive Antiretroviral Therapy.

Deme P, Rubin L, Yu D, Xu Y, Nakigozi G, Nakasujja N Viruses. 2022; 14(6).

PMID: 35746785 PMC: 9228482. DOI: 10.3390/v14061313.


References
1.
Gottlicher M, Minucci S, Zhu P, Kramer O, SCHIMPF A, Giavara S . Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001; 20(24):6969-78. PMC: 125788. DOI: 10.1093/emboj/20.24.6969. View

2.
Berges B, Akkina S, Remling L, Akkina R . Humanized Rag2(-/-)gammac(-/-) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year. Virology. 2009; 397(1):100-3. PMC: 3622870. DOI: 10.1016/j.virol.2009.10.034. View

3.
Scripture-Adams D, Brooks D, Korin Y, Zack J . Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol. 2002; 76(24):13077-82. PMC: 136703. DOI: 10.1128/jvi.76.24.13077-13082.2002. View

4.
Denton P, Olesen R, Choudhary S, Archin N, Wahl A, Swanson M . Generation of HIV latency in humanized BLT mice. J Virol. 2011; 86(1):630-4. PMC: 3255928. DOI: 10.1128/JVI.06120-11. View

5.
Clements J, Gama L, Graham D, Mankowski J, Zink M . A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system. Curr Opin HIV AIDS. 2011; 6(1):37-42. PMC: 3215305. DOI: 10.1097/COH.0b013e3283412413. View